Suppression of Rev3, the catalytic subunit of Pol zeta, sensitizes drug-resistant lung tumors to chemotherapy

Suppression of Rev3, the catalytic subunit of Pol zeta, sensitizes drug-resistant lung tumors to chemotherapy

Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymerase, Polζ [Pol zeta], can sensitize tumor cell...

Full description

Bibliographic Details
Main Authors: Doles, Jason D. (Contributor), Oliver, Trudy (Contributor), Cameron, Eleanor Ruth (Contributor), Hsu, Gerald (Author), Jacks, Tyler E. (Contributor), Walker, Graham C. (Contributor), Hemann, Michael (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: National Academy of Sciences (U.S.), 2011-07-20T20:09:29Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items